Relay Therapeutics Inc

RLAY remains in a Stage 2 advancing corrective reset within its long-term uptrend, but the formation of a Double Top and extreme overbought readings counsel against immediate entry. The medium-term bias stays bullish, yet timing is unfavorable as price sits extended above rising short-term EMAs and near overbought levels. Execution should be deferred until a shallow pullback into the 9EMA/21EMA zone shows acceptance and continuation potential. Primary risks include failure to hold these EMAs, confirmation of the Double Top via a break below its midpoint low, and a deeper retracement toward the 50 DMA.

• ↑60% volumetric response at 12 weeks for zovegalisib in Phase 2 ReInspire trial
• ↑Raised $275 M in public offering to fund trials and R&D
• ↓Severely negative profit margins highlight challenges in achieving profitability